Dr. Reddy’s Laboratories Ltd $RDY Shares Bought by Wealthstream Advisors Inc.

Wealthstream Advisors Inc. raised its holdings in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 52.1% in the second quarter, Holdings Channel.com reports. The fund owned 17,678 shares of the company’s stock after acquiring an additional 6,055 shares during the period. Wealthstream Advisors Inc.’s holdings in Dr. Reddy’s Laboratories were worth $266,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of RDY. Costello Asset Management INC purchased a new stake in Dr. Reddy’s Laboratories during the first quarter valued at about $26,000. Legacy Advisors LLC purchased a new stake in Dr. Reddy’s Laboratories during the first quarter valued at about $41,000. Allworth Financial LP lifted its stake in Dr. Reddy’s Laboratories by 28.4% during the first quarter. Allworth Financial LP now owns 3,504 shares of the company’s stock valued at $49,000 after buying an additional 776 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in Dr. Reddy’s Laboratories during the first quarter valued at about $62,000. Finally, Bayforest Capital Ltd purchased a new stake in Dr. Reddy’s Laboratories during the second quarter valued at about $76,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on RDY shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 8th. Zacks Research raised shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Dr. Reddy’s Laboratories presently has an average rating of “Moderate Buy” and an average target price of $16.95.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $14.44 on Friday. The company has a market capitalization of $12.05 billion, a price-to-earnings ratio of 21.87, a P/E/G ratio of 5.69 and a beta of 0.40. Dr. Reddy’s Laboratories Ltd has a fifty-two week low of $12.26 and a fifty-two week high of $16.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.89 and a quick ratio of 1.36. The business’s 50-day moving average is $14.30 and its 200-day moving average is $14.32.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. The company had revenue of $988.82 million for the quarter, compared to the consensus estimate of $88.27 billion. Dr. Reddy’s Laboratories had a return on equity of 17.25% and a net margin of 16.99%. Equities research analysts expect that Dr. Reddy’s Laboratories Ltd will post 0.8 EPS for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.